Tamoxifen and Tumor Immune Microenvironment Modulation: Mechanistic Reprogramming Across Myeloid, Endothelial, and Stromal Compartments

Tumor-associated macrophages (TAMs) contribute significantly to endocrine therapy resistance by sustaining an immunosuppressive stroma ^[1][2]. In estrogen receptor-positive (ER+) breast cancer, prolonged tamoxifen exposure frequently drives adaptive metabolic shifts characterized by elevated sodium/glucose cotransporter 1 (SGLT1) activity, enhanced glycolysis, and excessive lactic acid secretion ^[3]. This microenvironmental acidosis induces TAMs to adopt a protumor M2 phenotype governed by HIF-1α activation and STAT signaling, marked by augmented arginase-1 (Arg-1) and vascular endothelial growth factor (VEGF) secretion ^[3][4]. Crucially, cultured macrophages secrete high levels of CC-chemokine ligand 2 (CCL2), which triggers hyperactivation of downstream PI3K/Akt/mTOR pathways in adjacent tumor cells to counteract tamoxifen-mediated growth arrest ^[1][2][5]. Experimental interventions targeting macrophage activation overturn this protective signaling loop ^[4][6]. Pharmacological administration of tamoxifen directly blocks STAT6 signaling, leading to significant transcriptional suppression of classic M2 marker genes, including Arg-1, chitinase-like 3 (Chil3/Ym-1), resistin-like alpha (Retnla/Fizz-1), and mannose receptor C-type 1 (Mrc-1) ^[4]. Conversely, tamoxifen stimulates the production of nitric oxide and pro-inflammatory mediators such as interleukin-1β (IL-1β), IL-6, and TNF-α via TLR4 upregulation and MyD88-dependent nuclear factor-κB (NF-κB) phosphorylation ^[4][7]. In addition, tamoxifen suppresses the inhibitory immune checkpoints SHP1, SHP2, and SIRPα in macrophages and surrounding neoplastic cells ^[4]. Disruption of M2-driven trophic cytokines by tamoxifen diminishes secondary activation of the PI3K/Akt/mTOR cascade, restoring cytotoxic vulnerability across resistant breast cancer models ^[2][3][4][5].

Sialic acid-binding immunoglobulin-like lectins (Siglecs) operate as key regulators of myeloid immune tolerance and inflammatory threshold maintenance ^[1][7]. The paired receptor axis comprising Siglec-5, which possesses an immunoreceptor tyrosine-based inhibitory motif (ITIM), and Siglec-14, which recruits immunoreceptor tyrosine-based activation motif (ITAM)-bearing adapters, represents a critical checkpoint within the breast tumor immune microenvironment ^[4][7]. When human monocytic THP-1 cells were placed in co-culture models alongside ER+ MCF-7 or ER-negative MDA-MB-231 mammary carcinoma cells, exposure to 10 µM tamoxifen for 24 h profoundly rewired cytokine secretion profiles ^[7]. Tamoxifen treatment disrupted baseline checkpoint thresholds, stimulating high secretory yields of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8 in THP-1/MCF-7 transwell setups ^[4][7]. Mechanistically, tamoxifen drives the activation of caspase-1 to accelerate the maturation and release of active IL-1β ^[2][4][7]. While IL-10 concentrations remained largely undetectable in untreated control THP-1 cultures, MDA-MB-231 co-cultures exposed to tamoxifen demonstrated notable modulations in both IL-10 and bioactive heterodimeric IL-12p70 concentrations, reflecting microenvironmental adjustments dependent on neoplastic receptor status ^[7][8]. Parallel studies demonstrate that tamoxifen-mediated attenuation of phosphorylated SHP1 and SHP2 downstream of ITIM-bearing receptors, alongside reduced SIRPα surface expression, releases the myeloid brake on pro-inflammatory activation ^[4][7]. Furthermore, tamoxifen-induced metabolic reprogramming downregulates checkpoint evasion pathways, boosting the production of nitric oxide and tumoricidal mediators ^[4][9]. Together, these findings indicate that tamoxifen counteracts Siglec-5/14-dependent tolerance to re-establish an immunostimulatory tumor myeloid stroma ^[1][4][7].

Although historically restricted to gynecological cancers, tamoxifen exerts prominent non-classical activity across castration-resistant prostate cancer (CRPC) models expressing ERα ^[6][10]. Castration resistance frequently correlates with aberrant upregulation of the lipid kinase PIP5K1α and hyperactivation of its downstream effector Akt, which coordinates cell survival, invasion, and tumor spheroid formation ^[6]. In aggressive PC-3 xenograft models bearing established 400 mm³ tumors, pharmacological antagonism of ERα with tamoxifen significantly decreased cyclin D1 transcriptional activity and diminished PIP5K1α/Akt signal transduction ^[6]. Because tumor-associated macrophages (TAMs) frequently sustain residual tumor cell viability via trophic signaling, researchers coupled tamoxifen treatment with clodronate-encapsulated liposomes to deplete myeloid populations systemically ^[5][6]. The targeted elimination of TAMs combined with tamoxifen yielded marked reductions in ex vivo primary tumor spheroid growth compared to vehicle-treated controls or single-agent therapies ^[6]. At the mechanistic level, tamoxifen mitigates the macrophage-derived cytokine secretome, including CCL2 and IL-10, which otherwise stimulate stromal vascular endothelial growth factor receptor 2 (VEGFR2) and maintain Akt activation loops ^{[4][5][6][11]}. Depleting the macrophage barrier relieves endocrine insensitivity and prevents tumor-associated myeloid cells from reconstituting pro-angiogenic niches ^[5][6]. Moreover, tamoxifen inhibits the phosphorylation of SHP1 and SHP2 phosphatases within the residual tumor tissue, disrupting oncogenic receptor tyrosine kinase signaling ^[4][6]. Combining tamoxifen with macrophage eradication thus abolishes paracrine microenvironmental protection, providing substantial therapeutic efficacy against castration-resistant solid tumors ^[1][4][6].

Beyond epithelial tumor cells, tamoxifen exerts prominent mechanical and transcriptomic actions across the stromal and endothelial compartments of the tumor microenvironment ^[12][13]. In pancreatic ductal adenocarcinoma (PDAC) models, tamoxifen deactivates pancreatic stellate cells (PSCs), prompting the downregulation of 688 genes primarily involved in extracellular matrix (ECM) organization, cell adhesion, and response to hypoxia ^[12]. Genome-wide RNA sequencing and quantitative proteomics in KPC mice demonstrated that treatment with 5 mg tamoxifen elicited a fourfold reduction in the hypoxia marker GLUT1 and drove a twofold expansion in normalized CD31+ vascular structures ^[12]. Concurrently, tamoxifen repressed over 25 hypoxia-associated genes, including HIF-1A, thereby attenuating tumor tissue stiffness and mechanotransduction ^[12][14]. In immunocompetent mouse models grafted with ERα-negative B16K1 tumors, tamoxifen abolished 17β-estradiol (E2)-dependent tumor expansion by targeting host endothelial cells ^[13]. RNA sequencing revealed that tamoxifen completely blocked E2-induced transcriptional cascades and initiated a distinct endothelial gene signature that selectively regulates vessel normalization, differential glycolysis, oxidative phosphorylation, and localized inflammatory cascades ^[12][13]. By differentiating nuclear AF-1 and AF-2 transactivation from non-genomic membrane ERα actions, tamoxifen suppresses chaotic tumor neovascularization while improving structural perfusion ^[13]. In high-density 3D microfluidic tumor spheroid-endothelial chips, tamoxifen exposure additionally alters stromal resistance mediators, overcoming protective signals driven by IL-8, TIMP-1, and Serpin E1 ^[15]. Thus, tamoxifen acts as an effective anti-angiogenic and vessel-normalizing agent that reduces microenvironmental hypoxia across ER-negative stroma ^[12][13][15].

Recent structural and pharmacological studies reveal that tamoxifen directly targets the mitochondrial electron transport chain independently of classical ER transcription factor activity ^[9][16]. Tamoxifen suppresses mitochondrial respiratory complex I, precipitating a pronounced decline in oxidative phosphorylation (OXPHOS), depleting intracellular ATP pools, and triggering the sustained phosphorylation and activation of AMP-activated protein kinase (AMPK) ^[16]. To exploit this off-target vulnerability in vivo, investigators synthesized triphenylphosphonium-conjugated tamoxifen loaded into albumin nanoparticles (TPP-TAM@Alb) ^[9]. In aggressive triple-negative 4T1 murine mammary carcinoma models, TPP-TAM@Alb localized robustly to the mitochondrial network, dramatically depressing mitochondrial oxygen consumption rates ^[9]. This metabolic blockade reversed tumor hypoxia and directly downregulated the expression of immunosuppressive proteins, specifically programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) ^[9][16]. The simultaneous attenuation of PD-L1 and TGF-β disrupted stromal immune exclusion, curbing excessive collagen deposition and extracellular matrix cross-linking in the stroma ^[9][14][16]. Furthermore, combining TPP-TAM@Alb with paclitaxel albumin nanoparticles (PTX@Alb) stimulated extensive infiltration of cytotoxic CD8+ T cells into previously immune-excluded tumors ^[9]. Complementary evidence demonstrates that tamoxifen enhances antigen processing and presentation through major histocompatibility complex (MHC) class II upregulation via its primary active metabolite 4-hydroxy-N-desmethyltamoxifen (endoxifen) ^[8]. Therefore, metabolic disruption of complex I by tamoxifen-derived formulations relieves tumor immunosuppression, effectively substituting for clinical checkpoint blockade antibodies to convert immunologically cold tumors into immune-responsive niches ^{[1][8][9][16]}.

Neutrophils represent an abundant yet functionally plastic innate immune constituent within the peripheral circulation and solid tumor stroma ^[1][17]. Under standard physiological conditions, tumor-associated neutrophils frequently acquire protumorigenic, immunosuppressive properties; however, tamoxifen drives a rapid functional enhancement of neutrophil bactericidal and tumoricidal effector capabilities ^[1]. Mechanistically, tamoxifen modulates sphingolipid metabolic flux within human and murine neutrophils, stimulating the swift intracellular accumulation of bioactive ceramides ^[1][18]. Elevated ceramide generation promotes the rapid induction of neutrophil extracellular traps (NETs), marked by the extracellular extrusion of decondensed chromatin decorated with granular antimicrobial proteins and myeloperoxidase ^[1][18]. NETosis and concurrent oxidative burst generation markedly amplify innate cytotoxic killing of neighboring target cells ^[1]. When evaluated in equine peripheral blood mononuclear cells (PBMCs), tamoxifen demonstrated negligible overt cytotoxicity at low doses, but higher concentrations (10 µM) triggered significant transcriptional suppression of IL-4 without altering baseline GATA3, demonstrating high target specificity toward inflammatory phenotypes ^[17]. In parallel mouse models, tamoxifen-mediated remodeling of stromal biomechanics reduced collagen organization and tissue rigidity, allowing activated innate leukocytes to infiltrate dense matrix barriers ^[12][14]. Furthermore, when paired with antigen-specific lymphocyte vaccination targeting alpha-lactalbumin in breast cancer models, tamoxifen elicited a striking expansion of stromal B220+ leukocyte infiltration and dense CD3+, CD4+, and CD8+ T-cell clusters within the tumor stroma ^[19]. Tamoxifen-mediated ceramide shifts thus effectively boost the innate killing capacity of neutrophils while facilitating leukocyte trafficking through dense tumor stroma ^[1][12][19].

Regulatory T cells (Tregs), characterized by the master transcription factor forkhead box P3 (Foxp3) and surface expression of CD4 and CD25, enforce immune tolerance that restricts antitumor immunity ^[1][20]. Experimental evaluations across diverse mammalian systems demonstrate that tamoxifen dynamically influences CD4+ Foxp3+ regulatory T-cell expansion and phenotypic stability in a concentration-dependent manner ^[1][17]. In primary peripheral blood mononuclear cell (PBMC) cultures, incubation with varying concentrations of tamoxifen revealed notable threshold-dependent effects on immune-polarizing genes ^[17]. While lower concentrations retained normal cell viability, a 10 µM concentration provoked a marked downregulation of IL4 mRNA without triggering compensatory shifts in GATA3 expression, while keeping Th1-associated transcripts such as TBX21 and IFNG stable ^[17]. In vivo evaluations of postmenopausal early-stage breast cancer patients demonstrate that high baseline stromal tumor-infiltrating lymphocyte (sTIL) density and enriched IMMUNE1 gene expression modules correlate with differential endocrine responsiveness, whereas specific CD4, FOXP3, and PD1 gene expression levels alone do not fully dictate tamoxifen benefit ^[20]. Instead, tamoxifen selectively impairs Treg suppressive networks by attenuating downstream IL-10 secretion and downregulating suppressive immune checkpoint signaling modules ^[4][7][11]. Interestingly, in viral and parasitic challenge models, systemic tamoxifen administration depleted peripheral CD8+ T-cell frequencies and repressed cytotoxic memory responses during extended exposure, highlighting the fine balance between endocrine therapy and systemic immune tone ^[18][21]. These observations emphasize that optimizing the dosage of tamoxifen is vital for suppressing suppressive CD4+ Foxp3+ T-cell functions without compromising systemic effector immunity ^[1][17][20].

Elevated expression of interleukin-6 (IL-6) in the tumor microenvironment is strongly linked to therapeutic resistance, aggressive stromal desmoplasia, and cytotoxic T-cell exclusion ^[22][23]. In preclinical 7,12-dimethylbenz[a]anthracene (DMBA)-induced ER+ mammary carcinoma rat models, tamoxifen administration yielded profound systemic and intra-tumoral cytokine modulation ^[22]. Tamoxifen significantly depressed circulating serum concentrations of IL-6, as well as mRNA transcript levels of Il-6 within resected mammary tumor tissues ^[22]. The concurrent reduction of local and systemic IL-6 dismantled the immunosuppressive signaling milieu that generally blocks cytotoxic lymphocyte recruitment ^[22][23]. Analysis of tumor tissues from tamoxifen-treated cohorts demonstrated a marked increase in the infiltration of functional CD8a+ tumor-infiltrating lymphocytes (sTILs), establishing an active immunogenic microenvironment ^[22][23]. Splenic tissue analyses confirmed altered secondary lymphoid organ weights and an accompanying decrease in tolerogenic IL-10 levels ^[4][22]. In parallel murine hepatocellular carcinoma models driven by hepatitis B viral antigens, combining tamoxifen with anti-PD-1 checkpoint blockade yielded synergistic tumor regression and enhanced overall survival compared to monotherapy, which correlated directly with augmented CD8+ cytotoxic T-cell mobilization ^[23]. Furthermore, tamoxifen-mediated attenuation of IL-6 release suppressed local STAT3 and NF-κB hyperactivation within surrounding endothelial and myeloid cells, diminishing secondary pro-angiogenic VEGF release ^{[4][12][13][22]}. By lowering systemic and intratumoral IL-6 thresholds, tamoxifen effectively alleviates stromal immunosuppression, permitting cytotoxic CD8+ T lymphocytes to infiltrate and eradicate primary carcinomas ^[9][22][23].

Oral administration of tamoxifen exposes the gastrointestinal mucosa directly to high SERM concentrations, driving pronounced taxonomic shifts in the commensal gut microbiota ^[24]. In experimental murine breast cancer cohorts, tamoxifen treatment altered the microbial community structure, notably increasing the Firmicutes-to-Bacteroidetes ratio and depleting specific beneficial commensals ^[24]. This dysbiosis altered intestinal mucosal permeability and triggered local colonic inflammatory infiltration ^[24]. Mechanistically, tamoxifen downregulates Toll-like receptor 5 (TLR5) expression within intestinal epithelial cells, impairing flagellin recognition and disrupting gut barrier homeostasis ^[24]. In parallel, oral dietary administration of bovine lactoferrin (bLf) reversed tamoxifen-induced intestinal immunosuppression in 4T1 basal-like breast cancer models ^[25]. While single-agent tamoxifen caused noticeable intestinal mucosal blunting and depressed systemic interferon-gamma (IFN-γ) and IL-18 production, adjuvant bLf maintained elevated systemic levels of IFN-γ and IL-18, thereby boosting T, B, and natural killer (NK) cell mobilization to distal neoplastic lesions ^[25]. Moreover, in co-culture models, tamoxifen stimulated the release of the potent Th1-polarizing cytokine IL-12p70 in monocytic cells exposed to tumor secretomes, reinforcing systemic cell-mediated immune activation ^[7]. In pretreated rodent models, tamoxifen also prompted the sustained induction of interferon-stimulated genes, activating innate host defenses ^[18][22]. The complex interplay between gut microbiota shifts, mucosal TLR5 regulation, and circulating IL-12 and IFN-γ cascades underscores the broader systemic axis through which tamoxifen governs immune responses ^{[7][18][24][25]}.

At pharmacological and micromolar concentrations, tamoxifen induces functional inflammasome activation across monocytic and macrophage populations, representing an off-target immunomodulatory mechanism ^[2][4][7]. In human monocytic THP-1 cells co-cultured with breast cancer cells, exposure to 10 µM tamoxifen elicited significant upregulation of IL-1β secretion within 24 h ^[7]. Mechanistic dissection indicates that tamoxifen drives this response by triggering the proteolytic maturation of pro-caspase-1 into its enzymatically active subunits ^[2][4][7]. Active caspase-1 subsequently cleaves pro-IL-1β into its mature 17 kDa form, accelerating its exocytosis into the extracellular space ^[4][7]. Simultaneously, tamoxifen upregulates TLR4 and MyD88 protein levels in macrophages, activating the IKK kinase complex, enhancing the phosphorylation of IκB, and driving the nuclear translocation of NF-κB p65 ^[4]. This canonical signaling cascade boosts the transcription of pro-inflammatory factors, including IL-1β, IL-6, and TNF-α, while repressing the anti-inflammatory cytokines IL-10 and TGF-β ^[4][9]. Additionally, tamoxifen treatment decreases inhibitory phosphorylation of SHP1 and SHP2 while downregulating SIRPα receptor expression on monocytes, thereby removing inhibitory constraints on caspase-1 assembly ^[4][7]. In parallel ER+ breast cancer models, tamoxifen also stimulated the bystander release of peptidylprolyl isomerase B (PPIB), which induces endoplasmic reticulum stress and apoptotic signaling in adjacent ER-negative cells ^[26]. Through combined TLR4/MyD88/NF-κB axis activation, checkpoint inhibition, and caspase-1 cleavage, tamoxifen promotes mature IL-1β secretion, establishing a pro-inflammatory microenvironment that enhances tumoricidal clearance ^{[2][4][7][26]}.